Literature DB >> 30797942

Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.

Selim Corbacioglu1, Elias J Jabbour2, Mohamad Mohty3.   

Abstract

Veno-occlusive disease, also known as sinusoidal obstruction syndrome (VOD/SOS), is a potentially life-threatening complication of allogeneic or autologous hematopoietic stem cell transplantation (HSCT) most commonly associated with high-intensity chemotherapies. The development of VOD/SOS may be rapid and unpredictable, and the importance of identifying risk factors to facilitate prompt diagnosis and timely treatment has become increasingly recognized. The reporting of new retrospective study data for adults and children and the emergence of novel anticancer therapies that may increase the risk of VOD/SOD also necessitate updates on risk factors, as provided in this review. The latest studies reporting VOD/SOS risk factors support previously published data, although the importance of patient-related factors, such as acute kidney injury, increased international normalized ratio, female sex (in children), and platelet refractoriness, is given greater emphasis in the recent data. Non-transplantation-related chemotherapies associated with increased risk for VOD/SOS include oxaliplatin and 5-fluorouracil chemotherapies. The novel antibody drug conjugates gemtuzumab ozogamicin and inotuzumab ozogamicin are now reported in product labeling to pose risks for VOD/SOS based on clinical trial data; an expert consensus panel has issued recommendations for risk reduction measures with inotuzumab ozogamicin treatment, including VOD/SOS prophylaxis and limitation to ≤2 inotuzumab ozogamicin treatment cycles. A wide range of biomarkers, including genetic, hematologic, hepatic, and inflammatory factors, as well as novel diagnostic techniques such as thromboelastography and measures of liver stiffness, may further enhance future risk calculation for VOD/SOS, although none has been widely adopted. Continual monitoring for and recognition of VOD/SOS risk factors are essential for optimal management of this complication.
Copyright © 2019 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibody drug conjugates; Biomarkers; Primary chemotherapy; Risk factors; Veno-occlusive disease/sinusoidal obstruction syndrome

Mesh:

Substances:

Year:  2019        PMID: 30797942     DOI: 10.1016/j.bbmt.2019.02.018

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  28 in total

Review 1.  Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation.

Authors:  Mitchell S Cairo; Kenneth R Cooke; Hillard M Lazarus; Nelson Chao
Journal:  Br J Haematol       Date:  2020-03-04       Impact factor: 6.998

2.  Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT).

Authors:  Tiago Nava; Marc Ansari; Jean-Hugues Dalle; Christina Diaz de Heredia; Tayfun Güngör; Eugenia Trigoso; Ulrike Falkenberg; Alice Bertaina; Brenda Gibson; Andrea Jarisch; Adriana Balduzzi; Halvard Boenig; Gergely Krivan; Kim Vettenranta; Toni Matic; Jochen Buechner; Krzysztof Kalwak; Anita Lawitschka; Akif Yesilipek; Giovanna Lucchini; Christina Peters; Dominik Turkiewicz; Riitta Niinimäki; Tamara Diesch; Thomas Lehrnbecher; Petr Sedlacek; Daphna Hutt; Arnaud Dalissier; Jacek Wachowiak; Isaac Yaniv; Jerry Stein; Koray Yalçin; Luisa Sisinni; Marco Deiana; Marianne Ifversen; Michaela Kuhlen; Roland Meisel; Shahrzad Bakhtiar; Simone Cesaro; Andre Willasch; Selim Corbacioglu; Peter Bader
Journal:  Bone Marrow Transplant       Date:  2020-02-06       Impact factor: 5.483

3.  Drop of Butyrylcholinesterase Activity after Cyclophosphamide Conditioning as a Predictive Marker of Liver Transplant-Related Complications and Its Correlation with Transplant-Related Mortality in Pediatric Hematopoietic Stem Cell Recipients.

Authors:  Natalia Maximova; Giulia Caddeo; Davide Zanon; Alessandra Maestro; Roberto Simeone
Journal:  J Clin Med       Date:  2019-06-10       Impact factor: 4.241

4.  Introduction of new pediatric EBMT criteria for VOD diagnosis: is it time-saving or money-wasting? : Prospective evaluation of pediatric EBMT criteria for VOD.

Authors:  Zofia Szmit; Ewa Gorczynska; Anna Król; Marek Ussowicz; Monika Mielcarek-Siedziuk; Igor Olejnik; Anna Panasiuk; Krzysztof Kałwak
Journal:  Bone Marrow Transplant       Date:  2020-05-12       Impact factor: 5.483

Review 5.  Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies.

Authors:  Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2020-09-09       Impact factor: 2.490

6.  Ellipticine Conveys Protective Effects to Lipopolysaccharide-Activated Macrophages by Targeting the JNK/AP-1 Signaling Pathway.

Authors:  Li-Xing Tian; Xiao-Yu Li; Xin Tang; Xiao-Ying Zhou; Li Luo; Xiao-Yuan Ma; Wan-Qi Tang; Jing Yu; Wei Ma; Xue Yang; Jun Yan; Xiang Xu; Hua-Ping Liang
Journal:  Inflammation       Date:  2020-02       Impact factor: 4.092

7.  Successful diagnosis of veno-occlusive disease caused by inotuzumab ozogamicin through minimal-invasive angiography: a case report.

Authors:  Michiaki Sato; Megumi Yasunaga; Masami Ohzu; Kazuhiro Toyama; Kumi Nakazaki; Fumio Nakahara; Takatoshi Kubo; Naoki Okura; Osamu Abe; Mineo Kurokawa
Journal:  Ann Hematol       Date:  2021-12-02       Impact factor: 3.673

Review 8.  Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation.

Authors:  Amanda DeMauro Renaghan; Edgar A Jaimes; Jolanta Malyszko; Mark A Perazella; Ben Sprangers; Mitchell Howard Rosner
Journal:  Clin J Am Soc Nephrol       Date:  2019-12-13       Impact factor: 8.237

Review 9.  Genetic Predictors for Sinusoidal Obstruction Syndrome-A Systematic Review.

Authors:  Nicolas Waespe; Sven Strebel; Simona Jurkovic Mlakar; Maja Krajinovic; Claudia Elisabeth Kuehni; Tiago Nava; Marc Ansari
Journal:  J Pers Med       Date:  2021-04-26

Review 10.  Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia.

Authors:  Alexander Gavralidis; Andrew M Brunner
Journal:  Curr Hematol Malig Rep       Date:  2020-08       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.